Clinical Trial Update: Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing oxybutynin to paroxetine for vasomotor symptoms induced by aromatase inhibitors; efficacy and safety data are not yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vasomotor Symptoms

Drugs mentioned

• Paroxetine (Paroxetine hydrochloride)
• oxybutynin (oxybutynin)

Snippet

Sponsor: Cairo University | Conditions: Vasomotor Symptoms | Phase 3 | Status: UNKNOWN